Restasis Multidose

Heymann Nephritis, Lupus Nephritis, Nephrotic Syndrome + 30 more

Treatment

27 FDA approvals

20 Active Studies for Restasis Multidose

What is Restasis Multidose

Cyclosporine

The Generic name of this drug

Treatment Summary

Cyclosporine is a medication used to prevent organ rejection in transplant patients and treat certain autoimmune and inflammatory conditions. It is derived from a fungus called _Beauveria nivea_ and was first introduced in 1983 by the pharmaceutical company Sandoz (now Novartis).

Sandimmune

is the brand name

image of different drug pills on a surface

Restasis Multidose Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sandimmune

Cyclosporine

1983

68

Approved as Treatment by the FDA

Cyclosporine, also known as Sandimmune, is approved by the FDA for 27 uses which include Prophylaxis against heart transplant rejection and Heart Transplant Rejection .

Prophylaxis against heart transplant rejection

Heart Transplant Rejection

Therapeutic immunosuppression

Chronic Graft Versus Host Disease

Glomerulosclerosis, Focal Segmental

Helps manage Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis (FSGS)

Helps manage Focal Segmental Glomerulosclerosis (FSGS)

Prophylaxis against graft versus host disease

Liver

Liver Transplant Rejection

Heymann Nephritis

Helps manage Glomerulonephritis, Membranous

Glomerulosclerosis

Helps manage Glomerulosclerosis

severe, active Rheumatoid arthritis

Helps manage severe, active Rheumatoid arthritis

Patients who do not adequately respond to methotrexate alone

Used to treat Patients who do not adequately respond to methotrexate alone in combination with Methotrexate

Kidney Transplant Rejection

Steroid Resistant Nephrotic Syndrome

Helps manage Steroid Resistant Nephrotic Syndrome

Steroid Dependent Nephrotic Syndrome

Helps manage Steroid Dependent Nephrotic Syndrome

severe, recalcitrant Plaque psoriasis

Helps manage severe, recalcitrant Plaque psoriasis

Not responsive to other therapy

Helps manage Not responsive to other therapy

Bone Marrow Transplantation

Prophylaxis against stem cell transplant rejection

Transplantation

Rheumatoid Arthritis

Helps manage severe, active Rheumatoid arthritis

Nephrotic Syndrome

Helps manage Nephrotic Syndrome

Bone Marrow

Kidney Transplantation

Nephrotic Syndrome

Helps manage Steroid Resistant Nephrotic Syndrome

Nephrotic Syndrome

Helps manage Steroid Dependent Nephrotic Syndrome

Effectiveness

How Restasis Multidose Affects Patients

Cyclosporine helps to stop or reduce the effects of serious immune system reactions, such as after an organ transplant or bone marrow transplant. Common side effects include excessive hair growth, swollen gums, and high cholesterol levels. There is some concern that taking this drug may damage the kidneys.

How Restasis Multidose works in the body

Cyclosporine works by preventing T cells from becoming active and causing inflammation. It does this by preventing a certain receptor from binding to a protein called calcineurin, which helps activate T cells. This stops the production of cytokines, which are molecules that cause inflammation. It also lowers the levels of other molecules involved in T cell function and development.

When to interrupt dosage

The prescribed quantity of Restasis Multidose is dependent on the diagnosed circumstance, such as Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The dose is contingent upon the modality of administration (e.g. Liquid - Intravenous or Ophthalmic; Topical) presented in the table below.

Condition

Dosage

Administration

Nephrotic Syndrome

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Nephrotic Syndrome

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Prophylaxis against stem cell transplant rejection

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Patients who do not adequately respond to methotrexate alone

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Bone Marrow

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Conjunctivitis, Allergic

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Organ Transplantation

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Not responsive to other therapy

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Heymann Nephritis

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Rosacea

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Ulcerative Colitis

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Juvenile arthritis

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Cystitis, Interstitial

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Disease

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Bone Marrow Transplantation

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Chronic Graft Versus Host Disease

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Transplantation

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Dry Eye Syndromes

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Therapeutic immunosuppression

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Nephrotic Syndrome

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Warnings

Restasis Multidose Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Psoriasis

Do Not Combine

Abnormal Renal Function

Do Not Combine

Hypertensive disease

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Cyclosporine may interact with Pulse Frequency

There are 20 known major drug interactions with Restasis Multidose.

Common Restasis Multidose Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Cyclosporine.

Aliskiren

Major

The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Cyclosporine.

Restasis Multidose Toxicity & Overdose Risk

The toxic dose of cyclosporine in rats is 1480mg/kg, and the lowest toxic dose in humans is 12mg/kg. If someone takes too much cyclosporine, it is recommended to induce vomiting and perform a stomach lavage within 2 hours. There is not much information available about the effects of cyclosporine overdose, but it can lead to liver and kidney damage. In one case, a 26 year old woman experienced nausea, flushing, tremor, vertigo, and vomiting which resolved within 1 day. Anorexia and feeling of increased body girth were also reported and resolved within 2

image of a doctor in a lab doing drug, clinical research

Restasis Multidose Novel Uses: Which Conditions Have a Clinical Trial Featuring Restasis Multidose?

81 active trials are studying the potential of Restasis Multidose to provide therapeutic benefits for patients with Chronic Graft Versus Host Disease, Kidney Diseases and Ulcerative Colitis.

Condition

Clinical Trials

Trial Phases

Therapeutic immunosuppression

0 Actively Recruiting

Rheumatoid Arthritis

0 Actively Recruiting

Bone Marrow

1 Actively Recruiting

Early Phase 1

severe, recalcitrant Plaque psoriasis

0 Actively Recruiting

Nephrotic Syndrome

5 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Disease

0 Actively Recruiting

Prophylaxis against graft versus host disease

0 Actively Recruiting

Liver

0 Actively Recruiting

Heymann Nephritis

3 Actively Recruiting

Phase 2, Phase 1

Glomerulosclerosis

0 Actively Recruiting

Prophylaxis against heart transplant rejection

0 Actively Recruiting

Organ Transplantation

0 Actively Recruiting

Excessive tearing

0 Actively Recruiting

Transplantation

0 Actively Recruiting

Lupus Nephritis

24 Actively Recruiting

Phase 3, Phase 2, Phase 1, Phase 4

Not responsive to other therapy

0 Actively Recruiting

Kidney Transplantation

0 Actively Recruiting

Glomerulosclerosis, Focal Segmental

10 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4

Uveitis

3 Actively Recruiting

Not Applicable, Phase 3

Nephrotic Syndrome

0 Actively Recruiting

Restasis Multidose Reviews: What are patients saying about Restasis Multidose?

3.3

Patient Review

6/30/2018

Restasis Multidose for Dry Eye

The Restasis multidose dispenser bottle is not user-friendly. Too difficult to squeeze, and drops are wasted on the bottle nipple. I went back to single dose - which was easier to use and lasted much longer.

3.3

Patient Review

6/30/2018

Restasis Multidose for Dry Eye

The Restasis multidose dispenser bottle was not easy to use. I ended up wasting a lot of medication because it was difficult to control the amount of drops that came out.

3

Patient Review

7/2/2022

Restasis Multidose for Dry Eye

I wasn't thrilled with the design of the bottle. It seems like it would be easy to waste product. I'm going to try a generic brand next time.

3

Patient Review

7/2/2022

Restasis Multidose for Dry Eye

The multi-use bottle is very poorly designed. A cynical person might say that it was designed to waste product. I am going to try the generic cyclosporine.

2.7

Patient Review

2/26/2022

Restasis Multidose for Dry Eye

I've been using Restasis for years with the single-dose vials and never had a problem. The new multi-dose bottle is terrible. You have to squeeze it so hard to get anything to come out, and then more than one drop comes out. I can already tell this bottle won't last thirty days. They need to fix this!

2.7

Patient Review

2/26/2022

Restasis Multidose for Dry Eye

I've been using Restasis for years with the single-dose vials, and I never had a problem. The new multi-dose bottle is terrible. You have to squeeze it so hard to get anything to come out, and then more than one drop comes out. I can already tell this bottle won't last thirty days. They need to fix this!

2.7

Patient Review

4/2/2022

Restasis Multidose for Dry Eye

The drops are hard to dispense and the bottle doesn’t last but 20 days. This is very expensive for such a short amount of time, and I won't be buying it again.

2.7

Patient Review

4/2/2022

Restasis Multidose for Dry Eye

The drops are hard to dispense and the bottle doesn’t last but 20 days, which is very expensive. Will not buy again.

2

Patient Review

8/9/2018

Restasis Multidose for Dry Eye

The single-use doses of this medication were great, but I ran into issues when trying to use the bottle. The amount in each bottle never lasted long enough, and I often went weeks without any relief. Additionally, the price per month skyrockets if you need to use the individual vials rather than the bottles. Suffering from dry eyes is no fun, especially when you don't have access to your needed medication!

2

Patient Review

8/9/2018

Restasis Multidose for Dry Eye

The single-use doses were great, but when I moved to the bottle usage, it was awful. I never had enough drops, and would go weeks without any relief. The program is terrible - it only offers $5 if you use the bottles, and then goes up to $30 per month for the individual vials that work out in giving a 30 day supply as needed. I'm very unhappy and will be contacting my doctor to see if there is a different medication I can use. Suffering is not fun, especially when all you need is some eye drop relief!

1.7

Patient Review

10/2/2022

Restasis Multidose for Drying and Inflammation of Cornea and Conjunctiva of Eyes

The multi-dose container is very difficult to use, even for nurses with years of experience. I'm only supposed to use one drop in each eye, but it's impossible to control the amount that comes out. As a result, I go through this medication much faster than I should.

1.7

Patient Review

6/19/2021

Restasis Multidose for Dry Eye

The multi-dose version of this medication was very difficult to use and only lasted me 20 days, even though it is supposed to be a 30 day supply. In addition, it did not help at all with my dry eye problem. I'm considering trying the single vial next, even though it's more expensive.

1.7

Patient Review

10/2/2022

Restasis Multidose for Drying and Inflammation of Cornea and Conjunctiva of Eyes

I completely agree with the other negative reviews about how hard it is to get the right amount of medication out of the container. Even for a nurse with steady hands, it's impossible to use as directed. This product is clearly designed to make more money off of customers by not lasting very long.

1.7

Patient Review

6/19/2021

Restasis Multidose for Dry Eye

I found the multi-dose version to be very difficult to use, and it only lasted me 20 days instead of the 30 it was supposed to. Plus, it did nothing to help my dry eyes. I'm considering switching to the single-vial option, even though it's more expensive.

1.7

Patient Review

8/30/2022

Restasis Multidose for Dry Eye

The container design is really poor. You have to squeeze too hard for the product to come out, and then way too much comes out! Additionally, it's very difficult to get the product in my eyes. Awful!!

1.7

Patient Review

8/30/2022

Restasis Multidose for Dry Eye

The multi-use container is a joke. You have to squeeze really hard for anything to come out and then way too much comes out AND it’s impossible to get it right in my eyes. Awful!!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about restasis multidose

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much does Restasis MultiDose cost?

"The price of RESTASIS and RESTASIS MultiDose is $645.63 per month, plus any additional pharmacy charges depending on where you purchase your medicine."

Answered by AI

Is Restasis MultiDose available?

"RESTASIS is a medication that is FDA-approved to help patients with Chronic Dry eye produce more of their own tears. RESTASIS MultiDose is a preservative-free medication that is FDA-approved and available in a multidose bottle."

Answered by AI

How many drops are in a Restasis MultiDose bottle?

"A bottle of Restasis MultiDose contains approximately 120 doses or drops. The recommended dosage is one drop into each eye twice daily. This means that one bottle should last a little over 30 days."

Answered by AI

What is the difference between Restasis and Restasis MultiDose?

"The preservative-free formulation of RESTASIS that doctors have prescribed 6.4 million times since 2003 is available in a patented bottle design. Compared to the single-use vials of RESTASIS, the MultiDose version is more compact, uses less plastic in packaging, and is the same price."

Answered by AI

Clinical Trials for Restasis Multidose

Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

Ruxolitinib for T-Cell Lymphoma

18+
All Sexes
Columbus, OH

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Phase 2
Recruiting

Ohio State University Comprehensive Cancer Center

Jonathan Brammer, MD

Incyte Corporation

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Meal Macronutrients for Blood Fat Levels

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: * A resting metabolic test captures the air they exhale and measures how much energy they use at rest. * A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. * A Fibroscan is a special type of ultrasound of the liver. * A body surface scan uses lasers to measure the total area of the body. * A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Have you considered Restasis Multidose clinical trials?

We made a collection of clinical trials featuring Restasis Multidose, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Pain Mechanisms for Juvenile Arthritis

9 - 17
All Sexes
St Louis, MO

Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in children. The main symptoms of JIA, which are often the primary focus of treatment, include joint swelling, stiffness, and tenderness. Additional symptoms can include malaise, fatigue, and pain. However, the exact mechanisms contributing to pain are not yet fully understood. Participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed. In addition, demographic, social, pubertal maturation, and behavioral and psychological factors will be collected via questionnaires. A saliva sample and/or blood draw may occur for the analysis of various immune factors and sex hormones. If a joint aspiration is done as part of their standard of care, we will request a sample of the synovial fluid for analyses of immune, hormonal and/or genetic factors. Participants will have the option to participate in additional optional follow-up study visits (every 3 months, up to 1 year) and to complete monthly surveys asking about their juvenile arthritis.

Recruiting
Has No Placebo

Washington University School of Medicine

Hadas Nahman-Averbuch, PhD

Image of Allied Biomedical Research Institute in Miami, United States.

Cenerimod for Lupus Nephritis

18 - 75
All Sexes
Miami, FL

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.

Phase 3
Waitlist Available

Allied Biomedical Research Institute

Clinical Trials

Viatris Innovation GmbH

Image of Astera Cancer Care in East Brunswick, United States.

ALLO-329 for Lupus

18 - 69
All Sexes
East Brunswick, NJ

This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R).

Phase 1
Recruiting

Astera Cancer Care (+1 Sites)

Allogene Study Director

Allogene Therapeutics

Have you considered Restasis Multidose clinical trials?

We made a collection of clinical trials featuring Restasis Multidose, we think they might fit your search criteria.
Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Emapalumab for Graft-versus-Host Disease

18 - 75
All Sexes
Duarte, CA

This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.

Phase 1
Waitlist Available

City of Hope Medical Center

Amandeep Salhotra

Have you considered Restasis Multidose clinical trials?

We made a collection of clinical trials featuring Restasis Multidose, we think they might fit your search criteria.
Go to Trials